PBE · Invesco Biotechnology & Genome ETF ETF
Invesco Exchange-Traded Fund Trust
$97.64
-1.10%
At close · Sep 4
Net assets $247,382,628
Holdings30
1 month
+5.26%
Year to date
+20.13%
52-week range
$67.69–$98.82
30-session avg volume
46,922
Market performance
Adjusted close · up to five years
Fund profile
- Structure
- Exchange-traded product
- SEC series
- S000003026
- Report date
- Apr 30, 2026
- Holdings coverage
- Tracked U.S. equities
Portfolio concentration
Top 10 holdings—
Calculated only when the SEC filing is stored with complete portfolio coverage.
Portfolio holdings
Latest linked SEC Form NPORT-P report.
| Holding | Ticker / CUSIP | Value | Weight |
|---|---|---|---|
| United Therapeutics Corp. | UTHR | $15,547,576 | 6.28% |
| Illumina, Inc. | ILMN | $13,286,408 | 5.37% |
| Biogen Inc. | BIIB | $12,497,212 | 5.05% |
| Incyte Corp. | INCY | $12,146,830 | 4.91% |
| Alnylam Pharmaceuticals, Inc. | ALNY | $11,979,120 | 4.84% |
| Regeneron Pharmaceuticals, Inc. | REGN | $11,796,589 | 4.77% |
| Amgen Inc. | AMGN | $11,651,659 | 4.71% |
| Gilead Sciences, Inc. | GILD | $11,417,622 | 4.62% |
| BioCryst Pharmaceuticals, Inc. | BCRX | $8,458,875 | 3.42% |
| Catalyst Pharmaceuticals, Inc. | 14888U101 | $8,172,131 | 3.30% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | $8,110,282 | 3.28% |
| Protagonist Therapeutics, Inc. | PTGX | $7,958,673 | 3.22% |
| TG Therapeutics, Inc. | TGTX | $7,780,716 | 3.15% |
| Royalty Pharma PLC | RPRX | $7,753,481 | 3.13% |
| CareDx, Inc. | CDNA | $7,597,003 | 3.07% |
| Neurocrine Biosciences, Inc. | NBIX | $7,065,412 | 2.86% |
| Exelixis, Inc. | EXEL | $6,921,622 | 2.80% |
| Bio-Techne Corp. | TECH | $6,749,261 | 2.73% |
| PTC Therapeutics, Inc. | PTCT | $6,628,118 | 2.68% |
| Veracyte, Inc. | VCYT | $6,482,047 | 2.62% |
| Acadia Pharmaceuticals Inc. | ACAD | $6,415,918 | 2.59% |
| Vericel Corp. | VCEL | $6,380,804 | 2.58% |
| Halozyme Therapeutics, Inc. | HALO | $6,358,361 | 2.57% |
| Repligen Corp. | RGEN | $6,173,771 | 2.50% |
| Theravance Biopharma Inc. | TBPH | $6,172,105 | 2.49% |
| Ionis Pharmaceuticals, Inc. | IONS | $6,148,262 | 2.49% |
| BioMarin Pharmaceutical Inc. | BMRN | $6,050,050 | 2.45% |
| Collegium Pharmaceutical, Inc. | COLL | $5,247,646 | 2.12% |
| Qiagen N.V. | QGEN | $5,010,586 | 2.03% |
| MannKind Corp. | MNKD | $3,589,866 | 1.45% |